same conclusion. But GSK countered with private studies (conducted by the company itself!) that “prove” the safety of its molecule. GSK was simply asked to provide new studies, not expected before… 2020! With GSK’s patent on Avandia expiring in 2012, the bulk of the commercial risk would have long since passed.
Here we find the same scenario as in the scandals concerning NUJOL, LIPITOR, LYRICA, VIOXX, TAMIFLU, etc. This list has allowed us to review the main techniques of pharmaceutical companies, the most profitable mafia-like enterprises in the world, to